Longitudinally extensive transverse myelitis after Covid-19 vaccination: case report and review of literature

ABSTRACT

Mass vaccination has been the main policy to overcome the Covid-19 pandemic. Several vaccines have been approved by the World Health Organization. With growing vaccination, safety concerns and adverse events that need prompt evaluation are also emerging. Herein, we report a case of a healthy woman with longitudinally extensive transverse myelitis after vaccination with the AstraZeneca vaccine. The patient was successfully treated after ruling out all the possible causes.

KEYWORDS:

• Transverse myelitis
• Covid-19
• AstraZeneca

This article is referred to by:

Longitudinally extensive transverse myelitis after covid vaccination: Response to letter

Introduction

A number of neurological symptoms have been reported with Covid-19 infection. These include several central nervous system (CNS) manifestations such as acute cerebrovascular disease, transverse myelitis, encephalopathy, and peripheral nervous system (PNS) manifestations like Guillain–Barré syndrome.¹

The first Covid-19 vaccines were introduced in late 2020.² Since several cases of post-vaccination neurological disorders were reported, including Bellʻs Palsy,^3–5 Guillain–Barre syndrome,^6–8 and transverse myelitis.⁹

Transverse Myelitis (TM) is a clinical syndrome characterized by sensory, motor, and autonomic dysfunctions as a result of immune-mediated spinal cord injury.¹⁰ A few cases of acute TM have been described in the literature recently in association with Pfizer-BioNTech, Moderna, and Johnson & Johnsonʻs Covid-19 vaccines.^{11, 11–15} Here, we present a young female who presented with a longitudinally extensive TM following AstraZeneca vaccination against Covid-19.

Case presentation

A 31-year-old previously healthy woman presented to the emergency department with a 2-week history of progressive lower limbs paraparesis and paresthesia. Symptoms were more severe on the left side and were associated with pain in the left lower limb. She reported 1 week of urinary retention and 1 day of fecal incontinence prior to her presentation. Upon presentation, she was requiring assistance with ambulation and a urinary catheter was inserted. She denied any other neurologic or systemic symptoms. The patient had received first dose of Covid-19-Vaccine (AZD1222, AstraZeneca) 3 weeks prior to symptom onset. Her past medical history was significant for hyperthyroidism during pregnancy. She did not receive any medication. She had no known allergies. Physical examination revealed Medical Research Council (MRC) grade +4/5 in right lower limb and 3/5 in the left lower limb. Deep tendon reflexes were exaggerated in the lower limbs, and Babinski sign was present bilaterally. Sensory examination showed decreased pin prick sensation in lower limbs, impaired proprioception sensation in bilateral toes, and saddle anesthesia.

She underwent whole spine and brain Magnetic Resonance Imaging (MRI) with contrast. MRI revealed cord expansion and signal hyperintensity of the spinal cord from T10 to L1 segment with heterogeneous enhancement (Figure 1(a,b)). Initial laboratory parameters were normal. The SARS-CoV-2 RNA PCR nasal swab test was negative. Chest Computed Tomography (CT) Scan revealed no significant pathology. Lumbar puncture was performed; Cerebrospinal fluid (CSF) examination showed a white blood cell count (WBC) of 40, with 97% of lymphocytes. CSF chemistry revealed elevated protein (62 mg/dl), normal sugar (92 mg/dl) and lactate dehydrogenase (21 IU/L). Angiotensin-converting enzyme (ACE) and oligoclonal bands (OCBs) in CSF were negative. Additionally, CSF culture was negative. Anti-myelin oligodendrocyte glycoprotein (MOG) and anti neuromyelitis optica (NMO) antibodies in serum were negative. The paraneoplastic and rheumatologic screening were unremarkable. Patient was diagnosed with longitudinally extensive transverse myelitis and was treated with IV methylprednisolone 1 g per day for 7 days. The patient was discharged after improvement. She continued on oral prednisolone 50 mg daily and tapered over 1 month.

Figure 1. (a), (b) MRI reveals longitudinally extensive transverse myelitis from T10 to L1 with cord swelling and patchy/nodular enhancement, T2 and T1 with contrast, respectively; (c), (d) which turned to normal within 3 months followup, T2 and T1 with contrast, respectively.

The patient was reviewed 12 weeks later in clinic. She was able to walk without assistance. While her lower limbs power returned to normal, she continued to have left lower extremity spasticity and hyperreflexia along with a positive Babinski sign. She was also complaining of urinary frequency and saddle anesthesia. The follow-up MRI showed resolution of all changes seen in original MRI and no cord atrophy was detected (Figure 1(c,d)).

Discussion

TM is a neurological disorder characterized by inflammation of the spinal cord without a compressive lesion. Most commonly it is associated with multiple sclerosis, neuromyelitis optica and infections. TM manifests as an acute or sub-acute sensorimotor and autonomic dysfunction and sphincter disturbance.¹⁶ Other less common causes of TM are systemic diseases, paraneoplastic, and post-infectious conditions.¹⁷

TM has also been reported after vaccination. A recent study showed that the cervical spine was mostly involved followed by the thoracic segment.¹⁸ TM has been mostly described in association with Influenza vaccine followed by Hepatitis B vaccine.¹⁷

TM is mostly seen in patients in the second and fourth decade of life and affects around 1–8 million individuals annually.¹⁶ The phenomenon of autoimmunity is thought to cause TM after vaccination, and the most common reason is the presence of adjuvants in the composition of vaccines.¹⁸ A molecular mimicry between infectious antigens and self-antigens is proposed to be responsible for autoimmunity.¹⁷

Our patient was diagnosed with a longitudinally extensive transverse myelitis based on Transverse Myelitis Consortium Working Group.¹⁹ In this patient, TM was appeared 3 weeks after vaccination and the temporal relation between the first shot of vaccination and onset of symptoms was in keeping with post vaccination myelitis once all other potential etiologies were excluded appropriately. The patient was tested negative for Covid-19 therefore; a post-infectious myelitis was ruled out. Brain imaging did not show intracranial lesions and CSF examination did not show OCB, while NMO and MOG antibodies were not found either; therefore, multiple sclerosis (MS), NMO spectrum disorders and MOG-associated disorders were unlikely. Vasculitis and paraneoplastic screening were also unremarkable leaving the post-vaccination TM as the potential suspect.

Given widespread vaccination against Covid-19, recognition and timely management of this condition have become very important. TM has been reported both as a complication of Covid-19 infection and the Covid-19 vaccines. Currently, there are 254 reported cases of neurological adverse events according to Vaccine Adverse Event Reporting System, associated with Pfizer-BioNTech, Moderna, and Johnson & Johnsonʻs Covid-19 vaccines, of which 9 of them were TM.²⁰ As of today, all of these vaccines have caused vaccine-associated TM to a different extent.^{17, 21–23}

Given .5 per million incidences of Covid-19-associated TM, the incidence of TM associated with Covid-19 vaccine appears to be considerable. With widespread vaccination, increasing number of cases with post-vaccine TM have been reported.^{9, 11, 13, 15} The underlying mechanisms of AstraZeneca vaccine-induced TM are not yet known, it has been proposed that either the virus structural surface vector glycoprotein antigen or its chimpanzee adenovirus adjuvant could be the trigger for the autoimmunity process.⁹

In our case, after extensive workup, patientʻs symptoms could not be better explained by any alternative etiology other than post-vaccination TM. We believe her symptoms could not be associated with Covid-19 infection since she had negative PCR results both before¹⁰ and after vaccination and did not report any symptoms of Covid-19. To our knowledge, this is the second case of a longitudinally extensive TM reported after AstraZeneca vaccine against Covid-19.¹³ We have also included the results of 10 weeks follow-up, which was not previously reported. Our patient fully recovered clinically and radiologically with the exception of mild neurological signs on examination in keeping with a monophasic nature of this condition.

In conclusion, with the growing neurological impact of Covid-19, vaccine-associated disorders should be considered when approaching patients with neurological symptoms after either infection with the virus or vaccination against it. Although establishing the diagnosis of post-vaccination TM is challenging due to the fact it is based on ruling out other causes, its clinical importance should not be overlooked. Our case emphasis on the value of early recognition and prompt treatment in such cases.

Consent for publication

This case report was specifically discussed with the patient and informed consent was obtained.

References

• Ahmad I, Rathore FA. Neurological manifestations and complications of COVID-19: a literature review. J Clin Neurosci. 2020;77:8–4. doi:10.1016/j.jocn.2020.05.017.
   PubMed Web of Science ®Google Scholar
• Heinz FX, Stiasny K. Profiles of current COVID-19 vaccines. Wien Klin Wochenschr. 2021;133(7–8):271–83. doi:10.1007/s00508-021-01835-w.
   PubMed Web of Science ®Google Scholar
• Ozonoff A, Nanishi E, Levy O. Bellʻs palsy and SARS-CoV-2 vaccines. Lancet Infect Dis. 2021;21(4):450–52. doi:10.1016/s1473-3099(21)00076-1.
   PubMed Web of Science ®Google Scholar
• Cirillo N, Doan R. Bellʻs palsy and SARS-CoV-2 vaccines-an unfolding story. Lancet Infect Dis. 2021;21(9):1210–11. doi:10.1016/s1473-3099(21)00273-5.
   PubMed Web of Science ®Google Scholar
• Colella G, Orlandi M, Cirillo N. Bellʻs palsy following COVID-19 vaccination. J Neurol. 2021;21:1–3. doi:10.1007/s00415-021-10462-4.
   Google Scholar
• Márquez Loza AM, Holroyd KB, Johnson SA, Pilgrim DM, Amato AA. Guillain-Barré syndrome in the placebo and active arms of a COVID-19 vaccine clinical trial: temporal associations do not imply causality article-title. Neurology. 2021;96(22):1052–54. doi:10.1212/wnl.0000000000011881.
   Web of Science ®Google Scholar
• Waheed S, Bayas A, Hindi F, Rizvi Z, Espinosa PS. Neurological complications of COVID-19: Guillain-Barre syndrome following Pfizer COVID-19 vaccine. Cureus. 13(2), e13426. DOI: 10.7759/cureus.13426.
   PubMedGoogle Scholar
• Bourdette D, Killestein J. Quelling public fears About Guillain-Barré syndrome and COVID-19 vaccination. Neurology. 2021;96(22):1021–22. doi:10.1212/wnl.0000000000011882.
   Web of Science ®Google Scholar
• Román GC, Gracia F, Torres A, Palacios A, Gracia K, Harris D. Acute Transverse Myelitis (Atm):clinical review of 43 patients with COVID-19-associated ATM and 3 post-vaccination ATM serious adverse events with the ChAdox1 nCov-19 vaccine (AZD1222). Front Immunol. 2021;12:653786. doi:10.3389/fimmu.2021.653786.
   PubMed Web of Science ®Google Scholar
• Krishnan C, Kaplin AI, Deshpande DM, Pardo CA, and Kerr DA. Transverse Myelitis: pathogenesis, diagnosis and treatment. Frontiers in Bioscience: A Journal and Virtual Library. 2004 May 1;9(2):1483–99.
   PubMedGoogle Scholar
• Tahir N, Koorapati G, Prasad S et al. SARS-CoV-2 vaccination-induced transverse myelitis. Cureus. 2021;13(7):e16624.
   PubMedGoogle Scholar
• Erdem N, Demirci S, Özel T, Mamadova K, Karaali K, Çelik HT, Uslu FI, Özkaynak SS et al. Acute transverse myelitis after inactivated COVID-19 vaccine. Ideggyógyászati Szemle. 747–8:273–76. Akut transversalis myelitis inaktivált vírust alkalmazó Covid-19-vakcináció után. doi:10.18071/isz.74.0273.
   PubMedGoogle Scholar
• Pagenkopf C, Südmeyer M. A case of longitudinally extensive transverse myelitis following vaccination against Covid-19. J Neuroimmunol. ;358:577606. doi:10.1016/j.jneuroim.2021.577606.
   PubMedGoogle Scholar
• Alabkal J, Rebchuk A, Lyndon D, Randhawa N. Incomplete subacute transverse myelitis following vaccination with Pfizer-BioNtech COVID-19 mRNA vaccine: a case report. Cureus. 2021 ;12. doi:10.7759/cureus.20460.
   PubMedGoogle Scholar
• Gao J-J, Tseng H-P, Lin C-L, Shiu J-S, Lee M-H, Liu C-H. Acute transverse myelitis following COVID-19 vaccination. Vaccines. 2021;9(9). doi:10.3390/vaccines9091008.
   Google Scholar
• Sakakibara R, Hattori T, Yasuda K, Yamanishi T. Micturition disturbance in acute transverse myelitis. Spinal Cord. 1996 8 1;34(8):481–85. doi:10.1038/sc.1996.82.
   PubMed Web of Science ®Google Scholar
• Khan E, Shrestha AK, Colantonio MA, Liberio RN, Sriwastava S. Acute transverse myelitis following SARS-CoV-2 vaccination: a case report and review of literature. J Neurol. 2021;5:1–12.
   Google Scholar
• Shoenfeld Y, Aron-Maor A. Vaccination and autoimmunity—‘vaccinosisʻ: a dangerous liaison? J Autoimmun. 2000 2 1;14(1):1–10. doi:10.1006/jaut.1999.0346.
   PubMed Web of Science ®Google Scholar
• Transverse Myelitis Consortium Working Group*. Proposed diagnostic criteria and nosology of acute transverse myelitis. Neurology. 2002;59(4):499–505. doi:10.1212/WNL.59.4.499.
   PubMed Web of Science ®Google Scholar
• Goss AL, Samudralwar RD, Das RR, Nath A. ANA investigates: neurological complications of COVID-19 vaccines. Ann Neurol. 2021 5 1;89(5):856–57. doi:10.1002/ana.26065.
   PubMed Web of Science ®Google Scholar
• Knoll MD, Wonodi C. Oxford–astrazeneca COVID-19 vaccine efficacy. Lancet. 2021;397(10269):72–74. doi:10.1016/S0140-6736(20)32623-4.
   PubMed Web of Science ®Google Scholar
• Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, Angus B, Baillie VL, Barnabas SL, et al. Safety and efficacy of the ChAdox1 nCov-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397(10269):99–111. doi:10.1016/S0140-6736(20)32661-1.
   PubMed Web of Science ®Google Scholar
• Singh Malhotra H, Gupta P, Prabhu V, Kumar Garg R, Dandu H, Agarwal V. COVID-19 vaccination-associated myelitis. Qjm. 2021;114(8):591–93. doi:10.1093/qjmed/hcab069.
   PubMed Web of Science ®Google Scholar

Disclosure statement

No potential conflict of interest was reported by the author(s).

Additional information

Funding

The author(s) reported there is no funding associated with the work featured in this article.